LEMKE at Arab Health 2018
Arab Health was held from January 29th to February 1st 2018 at the International Convention & Exhibition Centre in Dubai, United Arab Emirates. Arab Health is the next largest and most important international medical trade fair after MEDICA and the largest in the Middle East. This event is expanding from a regional hub into a global meeting point.
We were proud to introduce our LEMKE-devices at a excellently designed and very well-located booth, in a strong partnership with our strategic partners ACL, NOUVAG and TONTARRA.
The highlight at this year’s event was the first presentation of the new GAMMA FINDER®. This new product with his innovative features earned a great response from distributors and doctors.
There were many visitors at our booth from the MEA region as well as from Asia. The multipurpose concept of LEMKE product portfolio in perfect combination with TONTARRA-Instruments prompted great attention from various booth visitors. Interesting and promising contacts have been made. Local distributors used our booth to efficiently present our brand and products to their key surgeons and decision makers with big success.
We hope this year’s Arab Health was a successful for you as it was for us and thank all of our visitors for the interesting conversations, sharing experiences and the needs of your markets. We highly appreciate your feedback, it will help us to make all of our businesses more successful.
Your LEMKE Team
LEMKE Product Service and Support Procedures
A step-by-step Guide to Streamline Your Service Request
As we welcome the new year at LEMKE, we would like to provide our latest checklist for requesting product service and support. Please review the below processes to make your experience as smooth and efficient as possible.
A) You notice a defect or fault on your device
1. Please contact the technical service at one of our locations via email or phone to estimate the extent of the problem (in Germany, contact Ludwigsstadt).
2. Should technical support be unable to help you, please contact customer service directly (in Germany, this is Berlin) or use an RMA form (return and repair processing form) available from our website under the heading "Sales & Service".
3. Please fill this form out and send it to customer service.
4. Our customer service team will directly contact you and provide you with an RMA number and information on how to return your device.
5. Next, please send this to the respective service location. (Note: To ensure traceability, returned equipment must be accompanied by an RMA number).
6. The customer service team will take care of the cost estimate and other details associated with processing your RMA request.
B) Your equipment is scheduled for regular maintenance
1. Please contact one of our customer service departments or use an RMA form (return and repair processing form) available on our website. Further steps as described above under "A," items 3-6.
C) Ordering replacement/spare parts
If you need a replacement part, please contact your customer service representative.
Before shipping equipment, decontaminate the device and accessories. Please confirm the successful decontamination in writing. If decontamination is not possible, the product must be sealed in two separate protective layers of foil, and clearly marked as contaminated on the delivery documents and on the package. If necessary, WOM has the right to reject contaminated products for repair.
In the event that WOM receives devices for repair without decontamination proof, please be informed that WOM will return the goods without repair at the expense of the sender. To avoid this inconvenience to you, please provide the necessary documents. Regulations require that the value of a device in need of repair corresponds to the actual value.
E) Return shipment
If a very low value is mentioned on the commercial invoice, WOM is obliged to clear the unit with a correct price during the import clearance process. WOM sets the import value as follows: sales price minus 10 % per year after date of purchase. Afterwards, WOM will re-export the device with the set import clearance value in compliance with German Customs Regulations.
Thank you for reviewing our service procedures. We look forward to providing you with excellent technical and customer service in the new year!
Your LEMKE Team
Low-Pressure Insufflation in Laparoscopic Surgery
Are there real benefits to the patient?
Insufflators are the devices that have advanced minimally invasive surgery (MIS) to the trend that it is today. Insufflators make it possible for surgeons to access internal organs with only a few small incisions. As MIS technology evolves, so does the demand for faster recovery times, minimal hospital stays, less pain and less risk to the patient.
For surgeons, an important goal in using an insufflator is to maintain a stable pneumoperitoneum during laparoscopic procedures. While routine intraabdominal pressure during insufflation is typically between 12-15 mmHg, the use of lower pressure may benefit certain patients. There have been a number of studies on low-pressure insufflation and most conclude that the most recognized benefit is reduced post-operative pain. The three types of pain in laparoscopic surgeries are deep intraabdominal pain (visceral pain), incisional pain (parietal pain) and shoulder pain (referred visceral pain). Pneumoperitoneum affects the visceral pain component and theoretically, lower abdominal pressure should reduce pain. For patients with comorbidities, there may be additional benefits beyond reduced post-op pain such as reduced cardiovascular effects. However, most studies conclude that less pain is the primary benefit to the patient.
Studies also emphasize caution as using pressures below 12 mmHg may affect visualization and careful consideration should be given based on factors such as the procedure type, complexity, and surgeons' experience. The LEMKE Insufflator 50 L quickly reacts to an unexpected drop in pressure which allows for a more stable pneumoperitoneum, even at pressures below 12 mmHg. With more than 29,500 units sold globally, the technology has proven to be reliable.
With the growing trend of value-based healthcare, less pain is of great importance to healthcare facilities. Increasingly, patients in markets such as the U.S. are surveyed after being treated and the information, such as pain scores, is considered in the procedure reimbursement. LEMKE devices, such as the Insufflator 50 L, continue to evolve with the demands of MIS practitioners and patients.
Your LEMKE Team
Sentinel Lymph Node Biopsy (SLNB) is the Gold Standard in Breast Cancer
The LEMKE Gamma Finder® II Provides Wireless SLN Detection and Ease of Use
It is known by oncologists and breast surgeons that removing multiple lymph nodes at the same time has been associated with adverse effects on breast cancer patients. For this reason, SLNB alone for staging breast cancer in women with no clinical signs of axillary lymph node metastasis, has become the gold standard of care.
The SLNB procedure is utilized in at least 65 % of breast cancer cases in the U.S. and EU, and just slightly lower in other countries. In the U.S. alone, approximately 253,000 cases of breast cancer will be diagnosed in 2017. There are many SLN detection devices on the market today, however, most are not completely handheld, wireless or convenient to use. What factors should be considered in selecting a gamma probe for SLNB? Of course high sensitivity, reliability and ease-of-use are important. The LEMKE Gamma Finder® II was developed with the surgeons in mind. Our handheld, wireless probe provides a clear display at your fingertips, audible sounds, an intuitive interface and high sensitivity for accurate detection of isotopes such as 99mTC. LEMKE is also regularly collecting surgeon feedback and gamma probe user insights to improve its devices such as the Gamma Finder® II.
SLNB is most commonly used to help stage breast cancer and melanoma. However, this technology is being observed for other cancer types as well, including colorectal cancer, gastric cancer, esophageal cancer, head and neck cancer, thyroid cancer, and non-small cell lung cancer. The Gamma Finder® II has proven to be a valuable device across the globe.
Your LEMKE Team